Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options_strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Springworks Therapeutics Inc (SWTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon BayStreet.ca - Thu Nov 14, 8:45AM CST

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon Newswire.ca - Thu Nov 14, 7:00AM CST

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark Zacks Investment Research - Wed Nov 13, 10:54AM CST

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...